

1 **Bone marrow stromal cell sheets promote axonal regeneration**  
2 **and functional recovery with suppressing glial scar formation**  
3 **after spinal cord transection injury in rats**

4  
5 Akinori Okuda, M.D.<sup>1,2\*</sup>, Noriko Horii-Hayashi, Ph.D.<sup>2</sup>, Takayo Sasagawa, M.S.<sup>2</sup>,  
6 Takamasa Shimizu, M.D., Ph.D.<sup>1</sup>, Hideki Shigematsu, M.D., Ph.D.<sup>1</sup>, Eiichiro Iwata,  
7 M.D.<sup>1</sup>, Yasuhiko Morimoto, M.D.<sup>1</sup>, Keisuke Masuda, M.D.<sup>1</sup>, Munehisa Koizumi M.D.,  
8 Ph.D.<sup>3</sup>, Manabu Akahane, M.D., Ph.D.<sup>4</sup>, Mayumi Nishi, M.D., Ph.D.<sup>2</sup>, and Yasuhito  
9 Tanaka, M.D., Ph.D.<sup>1</sup>

10  
11 <sup>1</sup>*Department of Orthopedic Surgery, Nara Medical University, Kashihara, Nara*  
12 *634-8522, Japan*

13 <sup>2</sup>*Department of Anatomy and Cell Biology, Faculty of Medicine, Nara Medical*  
14 *University, Kashihara, Nara 634-8521, Japan*

15 <sup>3</sup>*Spine and Spinal Cord Surgery Center, Nara Prefecture General Medical Center, Nara,*  
16 *631-0846, Japan*

17 <sup>4</sup>*Department of Public Health, Health Management, and Policy, Nara Medical*  
18 *University, Kashihara, Nara 634-8521, Japan*

19  
20 \*Corresponding author: Akinori Okuda, MD, Department of Orthopedic Surgery, Nara  
21 Medical University, Kashihara, Nara 634-8522, Japan

22 E-mail: [okuda74@naramed-u.ac.jp](mailto:okuda74@naramed-u.ac.jp)

23 Tel: +81-744-22-3051

1 Fax: +81-744-25-6449

2

3 **Keywords:** bone marrow stromal cell, cell sheet, axonal regeneration, spinal cord injury,

4 ascorbic acid, glial scar

5

6 **Running head:** BMSC sheets promote axonal regeneration in transected SCI rats

7

8 **Funding:** This work was supported by JSPS KAKENHI Grant Number 15K10417 to

9 Akinori Okuda, Noriko Horii-Hayashi, Takamasa Shimizu, Manabu Akahane, Mayumi

10 Nishi, and Yasuhito Tanaka.

11

1 **Abstract**

2 **OBJECT.** Transplantation of bone marrow stromal cells (BMSCs) is a  
3 theoretical potential as a therapeutic strategy in the treatment of spinal cord injury (SCI).  
4 Although a scaffold is sometimes used for retaining transplanted cells in damaged tissue,  
5 it is also known to induce redundant immunoreactions during the degradation processes.  
6 In this study, we prepared cell sheets made of BMSCs, which are transplantable without  
7 a scaffold, and investigated their effects on axonal regeneration, glial scar formation,  
8 and functional recovery in a completely transected SCI rat model.

9 **METHODS.** BMSC sheets were prepared from the bone marrow of female  
10 Fischer 344 rats using ascorbic acid, and were cryopreserved until the day of  
11 transplantation. A gelatin sponge (GS), as a control, or BMSC sheet was transplanted  
12 into a 2-mm-sized defect of the spinal cord at the T8 level. Axonal regeneration and  
13 glial scar formation were assessed 2 and 8 weeks after transplantation by  
14 immunohistochemical analyses using anti-Tuj1 and glial fibrillary acidic protein  
15 (GFAP) antibodies, respectively. Locomotor function was evaluated by the Basso,  
16 Beattie, Bresnahan (BBB) score.

17 **RESULTS.** The BMSC sheets promoted axonal regeneration at 2 weeks after  
18 transplantation, but there was no significant difference in the number of Tuj1-positive  
19 axons between the sheet- and GS-transplanted groups. At 8 weeks after transplantation,

1 Tuj1-positive axons elongated across the sheet and their numbers were significantly  
2 greater in the sheet group compared with the GS group. The areas of GFAP-positive  
3 glial scars in the sheet group were significantly reduced compared with those of the GS  
4 group at both time points. Finally, hind limb locomotor function was ameliorated in the  
5 sheet group at 4 and 8 weeks after transplantation.

6 **CONCLUSIONS.** The results of the present study indicate that an ascorbic  
7 acid-induced BMSC sheet is effective in the treatment of SCI and enables autologous  
8 transplantation without requiring a scaffold.

9

10

1           Accumulating evidence suggests that transplantation of adult bone marrow  
2   stromal cells (BMSCs) is a theoretical potential as a therapeutic strategy in the treatment  
3   of spinal cord injury (SCI). BMSCs are easily isolated and harvested *in vitro* and can be  
4   cryopreserved for a long duration.<sup>21</sup> BMSCs prepared from patients enable autologous  
5   transplantation. Previous studies have shown that BMSCs enhanced axonal regeneration  
6   and suppressed glial scar formation in both contused<sup>10,16,19,28,30</sup> and transected<sup>33</sup> SCI  
7   models. In the case of the transected model, a scaffold was still needed to fill the defect  
8   of the spinal cord as well as to retain the transplanted cells at the site.<sup>33</sup> Many kinds of  
9   scaffolds have been developed to date, including self-assembled peptide nanofibers,<sup>15</sup>  
10   gelatin,<sup>7</sup> collagen,<sup>26</sup> Matrigel,<sup>18</sup> and fibrin.<sup>17</sup> However, a previous report demonstrated  
11   that these biodegradable scaffolds induce inflammatory reactions during their  
12   degradation.<sup>32</sup> Thus, an autologous cell sheet that is transplantable without scaffolds is  
13   considered to be a useful material for the treatment of SCI.

14           BMSCs produce abundant extracellular matrix (ECM) proteins, which are  
15   considered suitable for tissue engineering applications.<sup>25</sup> Our previous study  
16   demonstrated that the addition of L-ascorbic acid phosphate (AscP) to the culture  
17   medium for BMSCs allowed the cells to disperse into a sheet form.<sup>20</sup> In the same study,  
18   the BMSC sheets were found to produce various growth factors such as vascular

1 endothelial growth factor, basic fibroblast growth factor (bFGF), platelet-derived  
2 growth factor, and insulin-like growth factor-1,<sup>20</sup> which have been reported to enhance  
3 axonal regeneration and to confer neuroprotection.<sup>11,12,31</sup> Thus, we hypothesized that  
4 transplanting a BMSC sheet into a spinal cord defect without a scaffold might enhance  
5 axonal regeneration and suppress glial scar formation. The aim of this study was to  
6 assess the usefulness of BMSC sheets in terms of axonal regeneration and the  
7 suppression of glial scar formation in a completely transected SCI model. We first  
8 examined the cell viability of BMSC sheets after recovery from cryopreservation and  
9 investigated their ECM components by immunocytochemical staining. Second, we  
10 examined whether the sheets are permissive for axonal elongation and the extension of  
11 astrocyte processes, using neurospheres co-cultured on the sheet, because previous work  
12 has shown that the permissiveness of transplants for astrocyte processes is also  
13 important to prevent glial scar formation *in vivo*.<sup>29</sup> Third, we investigated the number of  
14 regenerating axons and glial scar formation by immunohistochemical staining after  
15 transplantation of the BMSC sheet into a spinal cord defect. Finally, functional recovery  
16 was assessed by the Basso, Beattie, and Bresnahan locomotor rating scale (BBB scale).<sup>5</sup>

17

## 18 **Methods**

## 1 **Animals**

2 All experimental procedures were approved by the Institutional Animal Care  
3 and Use Committee of Nara Medical University. Female Fischer 344 rats were used in  
4 all experiments, which were purchased from Japan SLC Inc. (Shizuoka, Japan). A total  
5 of 30 rats were used for the experiments; 18 were used for histological and motor  
6 functional analyses (8-week-old rats), 10 were used for collecting bone marrow  
7 (7-week-old rats), and two embryos (embryonic day 17 [E17]) were used for preparing  
8 neurospheres.

9

## 10 **BMSC sheets**

11 The preparation of BMSCs from the femoral bone was performed as described  
12 previously,<sup>2,3,23</sup> and their application to cell sheets followed the methods described in  
13 our previous study.<sup>20</sup> In brief, bone marrow cells were obtained from the femoral shafts  
14 with standard culture medium: minimal essential medium (Nacalai Tesque, Kyoto,  
15 Japan) containing 15% fetal bovine serum (JRH Bioscience Inc., Lenexa, KS, USA) and  
16 antibiotics (100 U/mL of penicillin and 100 µg/mL of streptomycin; Nacalai Tesque).  
17 The released cells were collected in T-75 flasks (BD Falcon; BD Biosciences, Franklin  
18 Lakes, NJ, USA) with the medium and maintained in a humidified atmosphere with 5%

1 CO<sub>2</sub> at 37°C. After reaching confluence, the cells were trypsinized and seeded in 6-cm  
2 dishes (60 × 20 mm; BD Falcon) at 1 × 10<sup>4</sup> cells/cm<sup>2</sup> with the same medium containing  
3 0.28 mM of AscP magnesium salt n-hydrate (Wako Pure Chemical Industries, Kyoto,  
4 Japan). After 14 days in culture, the cells reached confluence and formed a sheet. The  
5 cell sheets were cryopreserved with CryoScarless medium (DMSO-Free; BioVerde, Inc.,  
6 Kyoto, Japan) according to the manufacturer instructions, and maintained at –80°C until  
7 transplantation.

8

#### 9 **Neurite growth and glial extension on BMSC sheets**

10 Neurospheres were prepared from the cortices of E17 embryos as described  
11 previously.<sup>27</sup> In brief, the tissues were dissociated by trituration with a fire-polished  
12 Pasteur pipette, and the cells were suspended in neurosphere culture medium:  
13 Dulbecco's modified Eagle medium/Ham's F-12 (1:1; Gibco, Carlsbad, CA, USA)  
14 containing 1% N2 supplement (Gibco), 1% penicillin/streptomycin (Nacalai Tesque),  
15 0.2% recombinant human bFGF (PeproTech, Rocky Hill, NJ, USA), and 2% B27  
16 supplement (Thermo Fisher, Waltham, MA, USA). Cells were seeded at 2 × 10<sup>5</sup>  
17 cells/mL in T-75 flasks containing the medium and incubated in 5% CO<sub>2</sub> at 37°C. After  
18 1 week, neurospheres were collected, trypsinized, and passaged to secondary culture.

1 After 3.5 days, the neurospheres were collected and cryopreserved with STEM  
2 CELL-BANKER (GMP-grade; Takara Bio Inc., Shiga, Japan) in liquid nitrogen until  
3 use. For co-culture of neurospheres and a BMSC sheet, thawed neurospheres  
4 were plated on BMSC sheets attached to poly-D-lysine-coated coverslips in a 24-well  
5 plate and maintained in neurosphere culture medium for 3.5 days in 5% CO<sub>2</sub> at 37°C.

6

### 7 **Cell viability assay**

8 Cryopreserved BMSC sheets were thawed at 37°C and rinsed twice with the  
9 standard culture medium. Trypsinized cells were centrifuged at 100 ×g for 5 min at 4°C.  
10 The cell pellets were re-suspended with the medium and stained with trypan blue  
11 solution (Nacalai Tesque). Cell counting was performed under a microscope using a  
12 hemocytometer. Cell viability was defined as follows: [(total cell number counted –  
13 number of stained cells)/total cell number counted] × 100. The viability of thawed  
14 BMSC sheets was compared with that of fresh BMSC sheets.

15

### 16 **SCI surgery**

17 Cryopreserved BMSC sheets were thawed on the day of surgery as described  
18 above and maintained in the standard culture medium until transplantation. Animals

1 were anesthetized with 2.0% isoflurane in 2.0 L/min oxygen and subjected to  
2 laminectomy at the T8 level, leaving the dura mater intact. The spinal cord was  
3 completely transected at two points 2 mm apart with microsurgical scissors, and the  
4 fragment of the spinal cord was removed. A BMSC sheet or gelatin sponge (GS) was  
5 transplanted into the defect to fill the space between the rostral and caudal stumps of the  
6 spinal cord. After transplantation, the muscles and skin were sutured layer by layer.  
7 Food and water were provided *ad libitum*. The bladder was pressed twice a day until  
8 spontaneous voiding began.

9

#### 10 **Assessment of locomotor function**

11 All locomotor assessments were performed by at least two examiners blinded  
12 to the group allocations. The hind limb locomotor functions of animals in both the  
13 BMSC sheet group (sheet group) and GS group were assessed using the BBB locomotor  
14 scale<sup>5</sup> at 1, 2, 4, and 8 weeks after transplantation. The BBB scale (from 0 to 21 points)  
15 can be used to assess locomotor recovery, including joint movements, stepping ability,  
16 coordination, and trunk stability. A score of 21 indicates unimpaired locomotion, as  
17 observed in uninjured rats.

18

## 1 **Immunostaining**

2           Histological and cytological immunostainings were performed as described  
3 previously.<sup>13,14</sup> In brief, cultured cells plated on poly-D-lysine-coated coverslips were  
4 fixed with 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer (pH 7.4) for 10 min.  
5 After permeabilization with 0.3% Triton X-100 in PBS (PBST), cells were blocked with  
6 5% normal horse serum (NHS) in PBST and incubated with Alexa  
7 Fluor-546-conjugated phalloidin and the following primary antibodies: mouse  
8 anti-collagen I (1:100; Abcam, Cambridge, UK), rabbit anti-collagen IV (1:100; Progen,  
9 Heidelberg, Germany), guinea pig anti-laminin (1:200; gifted from Dr. Miyata),<sup>22</sup>  
10 mouse anti-Tuj1 (1:200; Covance, Princeton, NJ, USA), or rabbit anti- glial fibrillary  
11 acidic protein (GFAP; 1:1000; Abcam). They were further incubated with  
12 species-specific secondary antibodies conjugated with Alexa Fluor-488 (1:1000;  
13 Thermo Fisher) or CF-555 (1:1000; Biotium, Hayward, CA, USA). The coverslips were  
14 shielded using Vectashield containing 4',6-diamidino-2-phenylindole (DAPI; Vector,  
15 Burlingame, CA, USA).

16           For immunohistochemistry, anesthetized animals with sodium pentobarbital  
17 (100 mg/kg) were transcardially perfused with PBS followed by 4% PFA. Dissected  
18 T6–T10 spinal cord segments were post-fixed with the same fixative overnight. After

1 cryoprotection with 30% sucrose in PBS, 20- $\mu$ m-thick sagittal sections were made with  
2 a cryostat (Leica, Wetzler, Germany) and mounted on glass slides. The sections were  
3 treated with 25 mM glycine in PBS, 0.3% PBST, and then blocked in PBST containing  
4 5% NHS for 2 h. The sections were incubated with the following primary antibodies for  
5 2 days at 4°C: mouse anti-Tuj1 (1:200; Covance), rabbit anti-Tuj1 (1:200; Covance),  
6 mouse anti-GAP43 (1:100; Millipore, Bedford, MA, USA), rabbit anti-GFAP (1:1000;  
7 Abcam), or guinea pig anti-laminin. The sections were incubated with species-specific  
8 secondary antibodies conjugated with Alexa Fluor-488 or CF-555 (1:1000; Biotium) for  
9 2 h. The coverslips were shielded using Vectashield containing DAPI. All  
10 immunocytochemical and immunohistochemical images were captured using a  
11 FluoView 1000 confocal microscope (Olympus, Tokyo, Japan) with a 512  $\times$  512-pixel  
12 array.

13

#### 14 **Quantification of axonal regeneration and glial scarring**

15 Axonal regeneration and glial scar formation were analyzed using the  
16 morphometric software program Metamorph (Molecular Devices, Sunnyvale, CA,  
17 USA). Nine serial sections prepared at 80- $\mu$ m intervals including the midline were  
18 analyzed per animal. The numbers of regenerating axons were quantified by counting

1 the numbers of Tuj1-positive axons with a length of at least 50  $\mu\text{m}$  within the two  
2 rectangles ( $500 \times 1000 \mu\text{m}^2$ ) that were 400  $\mu\text{m}$  away from the rostral and caudal stumps  
3 of the injury sites. Glial scar formation was quantified by measuring the GFAP-positive  
4 areas within the two rectangles ( $1250 \times 500 \mu\text{m}^2/\text{area}$ ) including the rostral and caudal  
5 edges of the injury sites. The numbers of axons and GFAP-positive areas obtained from  
6 nine sections were summed as the final numbers and areas, respectively.

7

## 8 **Statistical analyses**

9         The Kolmogorov-Smirnov test, Shapiro-Wilk test, F-test, t-test, or Welch's test  
10 was performed depending on whether the data followed a normal distribution. The t-test  
11 was performed to examine significant differences in glial scar area, and Welch's test  
12 was performed to determine significant improvements in axonal regeneration.  
13 Furthermore, the t-test and repeated-measures analysis of variance were performed to  
14 examine significant improvements in BBB scores. All data are presented as means  $\pm$   
15 SEM. Data analyses were conducted using the Statistical Package for the Social  
16 Sciences (SPSS) software package (version 23.0; SPSS Inc., Chicago, IL, USA). A  
17 probability value ( $p$ )  $< 0.05$  was considered to denote statistical significance.

18

## 1 **Results**

### 2 **Cell viability of cryopreserved BMSC sheets**

3           The cell viability of the BMSC sheets after cryopreservation was  $92.88 \pm$   
4 1.32% ( $n = 7$ ), which was considered to represent good recovery after freezing. We  
5 therefore used cryopreserved BMSC sheets for all transplantation experiments.

6

### 7 **The BMSC sheets provided neural cells with a permissive environment for** 8 **elongation *in vitro***

9           BMSC sheets prepared using AscP were easily detached from the culture dishes  
10 with a cell scraper (Fig. 1A) and could be lifted up with forceps (Fig. 1B).  
11 Immunohistochemical results showed that BMSC sheets expressed collagen I and  
12 laminin (Fig. 1C and 1E), but not collagen IV (Fig. 1D). Immunostaining of  
13 neurospheres cultured on a BMSC sheet revealed that both Tuj1-positive neurites and  
14 GFAP-positive astrocyte processes could elongate on the sheet (Fig. 1F). These results  
15 indicated that the BMSC sheets do not inhibit the elongation of axons and astrocyte  
16 processes.

17

### 18 **BMSC sheets promoted axonal regeneration**

1           A spinal cord defect (Fig. 2A) was filled with a folded BMSC sheet (Fig. 2B)  
2 or GS (Fig. 2C). Two weeks after transplantation, double labeling of Tuj1 and GAP43 (a  
3 marker for growing axons) was performed. The results showed that the majority of  
4 Tuj1-positive axons at the sheet-transplanted site overlapped with GAP43-positive  
5 axons (Fig. 3A), indicating that almost all axons at the injured site were regenerating  
6 axons.

7           Double labeling of Tuj1 and GFAP was performed at 2 and 8 weeks after  
8 transplantation. More Tuj1-positive axons beyond the GFAP-positive glial scar were  
9 observed in sheet-transplanted rats compared with GS-transplanted rats at 2 weeks after  
10 transplantation (Fig. 3B). At 8 weeks after transplantation, elongated Tuj1-positive  
11 axons crossed the transplanted site in the sheet-transplanted animals, but not in the  
12 GS-transplanted animals (Fig. 3C). The number of Tuj1-positive axons (green boxes in  
13 Fig. 3D) was significantly greater in the sheet group compared with the GS group at 8  
14 weeks after transplantation (Fig. 3E; BMSC,  $429 \pm 97.17$ ; GS,  $118 \pm 19.84$ ;  $p = 0.047$ ,  $n$   
15  $= 4$  per group). However, there was no significant difference ( $p = 0.124$ ) between the  
16 sheet and GS groups at 2 weeks after transplantation (Fig. 3E; BMSC,  $64.75 \pm 25.00$ ;  
17 GS,  $12.25 \pm 5.79$ ,  $n = 4$  per group). These results indicate that BMSC sheets promote  
18 axonal regeneration after SCI.

1

2 **BMSC sheets attenuated glial scar formation and affected the shape of the glial**  
3 **scar**

4           GFAP immunoreactivity in the rostral and caudal spinal cord stumps appeared  
5 weaker in the sheet-transplanted rats compared with those of the GS-transplanted rats at  
6 2 and 8 weeks after transplantation (Fig. 4A and 4B). Furthermore, GFAP  
7 immunoreactivity at 8 weeks after transplantation showed an irregular and straggly  
8 shape lengthwise in the rostro-caudal direction in sheet-transplanted animals, whereas it  
9 showed a tightly packed shape with the spinal cords walled off from the transplant at the  
10 rostral and caudal stumps in GS-transplanted animals (Fig. 4C). GFAP-positive areas  
11 (black-outlined boxes in Fig. 4D) in the sheet group were significantly reduced  
12 compared with those of the GS group at both time points (Fig. 4E, 2 weeks: BMSC, 799  
13  $429 \pm 71\ 588\ \mu\text{m}^2$ ; GS,  $159\ 0592 \pm 190\ 938\ \mu\text{m}^2$ ;  $p = 0.008$ ,  $n = 4$ ; 8 weeks: BMSC, 403  
14  $005 \pm 95\ 128\ \mu\text{m}^2$ ; GS:  $130\ 5847 \pm 186\ 634\ \mu\text{m}^2$ ;  $p = 0.005$ ,  $n = 4$  per group). These  
15 results indicated that the BMSC sheets attenuated glial scar formation after SCI with  
16 affecting the shape of reactive astrocytes.

17

18

## 1 **BMSC sheets improved locomotor function compared to GS**

2           The BBB scores were measured at 0, 1, 2, 4, and 8 weeks after transplantation  
3 (Fig. 5). Significant differences in BBB scores between the sheet and GS groups were  
4 observed at 4 weeks (sheet:  $5.13 \pm 0.32$ ; GS:  $2.75 \pm 0.48$ ;  $p < 0.05$ ,  $n = 6$ ) and 8 weeks  
5 (sheet:  $5.25 \pm 0.14$ ; GS:  $3.00 \pm 0.29$ ;  $p < 0.05$  vs. GS,  $n = 6$ ) after transplantation. These  
6 results indicated that the BMSC sheet improved locomotor function compared with GS  
7 transplantation.

## 9 **Discussion**

10       Several studies have demonstrated that transplantation of BMSCs (non-sheet form)  
11 was effective for axonal regeneration and enhanced hind limb motor function in both  
12 contusive<sup>4,8,24</sup> and transected<sup>33</sup> SCI rat models. The present study demonstrates that the  
13 sheet form of BMSCs is also effective for promoting axonal regeneration and functional  
14 improvement in a transected SCI model. Transplanted BMSCs do not tend to  
15 differentiate into neural cells in the host's central nervous system.<sup>6,9</sup> Thus, the observed  
16 regenerating axons from the rostral to caudal stumps are considered to be the hosts'  
17 neurons.

18       Recent evidence has shown that the inhibition of axonal regeneration is mainly due to

1 the formation of a glial scar, which is a type of secondary damage following SCI.<sup>34</sup> The  
2 present study also showed that BMSC sheets suppress glial scar formation in the same  
3 manner as observed for the non-sheet form of BMSCs.<sup>1,10,24,30</sup> Considered together with  
4 the result of the co-culture experiment of the sheet and neurospheres, BMSC sheets  
5 seem to provide a permissive environment for injured axons. Recent evidence suggests  
6 that a glial scar formed by GFAP-positive astrocytes does not always inhibit axonal  
7 regeneration, but rather the shape of the scar is a more important factor for its inhibitory  
8 effect.<sup>29</sup> The same study described that the penetration of astrocyte processes into a  
9 transplant is an indicator of a permissive environment for axonal regeneration. Our  
10 results showed that GFAP-positive processes were elongating toward the  
11 sheet-transplanted site, especially at 8 weeks after transplantation. In contrast, these  
12 features were not observed in the GS-transplanted site, where tightly packed  
13 GFAP-positive astrocytes walled off the spinal cord from the transplant. These results  
14 demonstrate that BMSC sheets not only suppress glial scar formation but also likely  
15 provide a good environment for the regeneration of injured axons by affecting the  
16 morphology of reactive astrocytes.

17 Cell sheet technology has attracted broad attention in tissue engineering because  
18 transplanted cell sheets can maintain their biological activity and prevent the spilling out

1 of transplanted cells without scaffolds. Most cases of SCI in clinical settings result from  
2 contusion, and the chronic phase involves the formation of cavities and a glial scar.  
3 Although the present study used a transection model of SCI, we suppose that BMSC  
4 sheets would also be clinically useful for filling these cavities. Another possible usage  
5 of BMSC sheets is to fill the defect formed after surgical resection of the glial scar,  
6 because the scar can be the wall inhibiting regenerating axons even after cell  
7 transplantation. Finally, the present study showed that co-culture of neurospheres and  
8 BMSC sheets is possible, which highlights the potential for the co-culture of BMSC  
9 sheets and neural stem cells derived from induced pluripotent stem cells as a great step  
10 towards clinical application. Further studies are needed before clinical trials of BMSC  
11 sheets can be conducted, such as experiments using non-human primates.

12

### 13 **Conclusions**

14 The present study indicates the potential therapeutic effects of BMSC sheets for  
15 SCI, which would enable autologous transplantation without requiring scaffolds.

16

### 17 **Conflict of interest**

18 The authors report no conflict of interest concerning the materials or methods

1 used in this study or the findings specified in this paper.

2

3

## 1 **Acknowledgements**

2           We thank Haruo Kanno, Satoshi Tateda, and Kenichiro Yahata (Tohoku  
3 University School of Medicine, Japan) for technical advice; and Fumika Kunda and  
4 Yumi Moriwake (Nara Medical University School of Medicine, Japan) for technical  
5 assistance. This work was supported by JSPS KAKENHI Grant Number 15K10417.

6

## 1     **References**

2

- 3     1.     Abrams MB, Dominguez C, Pernold K, Reger R, Wiesenfeld-Hallin Z, Olson L,  
4           et al: Multipotent mesenchymal stromal cells attenuate chronic inflammation  
5           and injury-induced sensitivity to mechanical stimuli in experimental spinal cord  
6           injury. **Restor Neurol Neurosci** 27:307–321, 2009
- 7     2.     Akahane M, Nakamura A, Ohgushi H, Shigematsu H, Dohi Y, Takakura Y:  
8           Osteogenic matrix sheet-cell transplantation using osteoblastic cell sheet resulted  
9           in bone formation without scaffold at an ectopic site. **J Tissue Eng Regen Med**  
10          2:196–201, 2008
- 11    3.     Akahane M, Shigematsu H, Tadokoro M, Ueha T, Matsumoto T, Tohma Y, et al:  
12          Scaffold-free cell sheet injection results in bone formation. **J Tissue Eng Regen**  
13          **Med** 4:404–411, 2010
- 14    4.     Ankeny DP, McTigue DM, Jakeman LB: Bone marrow transplants provide  
15          tissue protection and directional guidance for axons after contusive spinal cord  
16          injury in rats. **Exp Neurol** 190:17–31, 2004
- 17    5.     Basso DM, Beattie MS, Bresnahan JC, Anderson DK, Faden AI, Gruner JA, et  
18          al: MASCIS evaluation of open field locomotor scores: effects of experience and  
19          teamwork on reliability. Multicenter Animal Spinal Cord Injury Study. **J**

- 1           **Neurotrauma** **13**:343–359, 1996
- 2   6.       Castro RF, Jackson KA, Goodell MA, Robertson CS, Liu H, Shine HD: Failure  
3       of bone marrow cells to transdifferentiate into neural cells in vivo. **Science**  
4       **297**:1299, 2002
- 5   7.       Chen MH, Chen PR, Hsieh ST, Huang JS, Lin FH: An in vivo study of  
6       tricalcium phosphate and glutaraldehyde crosslinking gelatin conduits in  
7       peripheral nerve repair. **J Biomed Mater Res B Appl Biomater** **77**:89–97, 2006
- 8   8.       Chopp M, Zhang XH, Li Y, Wang L, Chen J, Lu D, et al: Spinal cord injury in  
9       rat: treatment with bone marrow stromal cell transplantation. **Neuroreport**  
10       **11**:3001–3005, 2000
- 11   9.       Coyne TM, Marcus AJ, Woodbury D, Black IB: Marrow stromal cells  
12       transplanted to the adult brain are rejected by an inflammatory response and  
13       transfer donor labels to host neurons and glia. **Stem Cells** **24**:2483–2492, 2006
- 14   10.       Dasari VR, Veeravalli KK, Dinh DH: Mesenchymal stem cells in the treatment  
15       of spinal cord injuries: A review. **World J Stem Cells** **6**:120–133, 2014
- 16   11.       Davis JB, Stroobant P: Platelet-derived growth factors and fibroblast growth  
17       factors are mitogens for rat Schwann cells. **J Cell Biol** **110**:1353–1360, 1990
- 18   12.       Hokari M, Kuroda S, Shichinohe H, Yano S, Hida K, Iwasaki Y: Bone marrow

- 1 stromal cells protect and repair damaged neurons through multiple mechanisms.  
2 **J Neurosci Res** **86**:1024–1035, 2008
- 3 13. Horii-Hayashi N, Sasagawa T, Hashimoto T, Kaneko T, Takeuchi K, Nishi M: A  
4 newly identified mouse hypothalamic area having bidirectional neural  
5 connections with the lateral septum: the perifornical area of the anterior  
6 hypothalamus rich in chondroitin sulfate proteoglycans. **Eur J Neurosci**  
7 **42**:2322–2334, 2015
- 8 14. Horii-Hayashi N, Sasagawa T, Matsunaga W, Nishi M: Development and  
9 structural variety of the chondroitin sulfate proteoglycans-contained  
10 extracellular matrix in the mouse brain. **Neural Plast** **2015**:256389, 2015
- 11 15. Huang YC, Huang YY: Biomaterials and strategies for nerve regeneration. **Artif**  
12 **Organs** **30**:514–522, 2006
- 13 16. Ide C, Nakai Y, Nakano N, Seo TB, Yamada Y, Endo K, et al: Bone marrow  
14 stromal cell transplantation for treatment of sub-acute spinal cord injury in the  
15 rat. **Brain Res** **1332**:32–47, 2010
- 16 17. Ju YE, Janmey PA, McCormick ME, Sawyer ES, Flanagan LA: Enhanced  
17 neurite growth from mammalian neurons in three-dimensional salmon fibrin gels.  
18 **Biomaterials** **28**:2097–2108, 2007

- 1 18. Kamada T, Koda M, Dezawa M, Anahara R, Toyama Y, Yoshinaga K, et al:  
2 Transplantation of human bone marrow stromal cell-derived Schwann cells  
3 reduces cystic cavity and promotes functional recovery after contusion injury of  
4 adult rat spinal cord. **Neuropathology** 31:48–58, 2011
- 5 19. Kang KN, Lee JY, Kim da Y, Lee BN, Ahn HH, Lee B, et al: Regeneration of  
6 completely transected spinal cord using scaffold of  
7 poly(D,L-lactide-co-glycolide)/small intestinal submucosa seeded with rat bone  
8 marrow stem cells. **Tissue Eng Part A** 17:2143–2152, 2011
- 9 20. Kira T, Omokawa S, Akahane M, Shimizu T, Nakano K, Nakanishi Y, et al:  
10 Effectiveness of bone marrow stromal cell sheets in maintaining random-pattern  
11 skin flaps in an experimental animal model. **Plast Reconstr Surg** 136:624e–  
12 632e, 2015
- 13 21. Lalu MM, McIntyre L, Pugliese C, Fergusson D, Winston BW, Marshall JC, et  
14 al: Safety of cell therapy with mesenchymal stromal cells (SafeCell): a  
15 systematic review and meta-analysis of clinical trials. **PLoS One** 7:e47559,  
16 2012
- 17 22. Mannari T, Sawa H, Furube E, Fukushima S, Nishikawa K, Nakashimna T, et al:  
18 Antidepressant-induced vascular dynamics in the hippocampus of adult mouse

- 1 brain. **Cell Tissue Res** **358**:43–55, 2014
- 2 23. Nakamura A, Akahane M, Shigematsu H, Tadokoro M, Morita Y, Ohgushi H, et  
3 al: Cell sheet transplantation of cultured mesenchymal stem cells enhances bone  
4 formation in a rat nonunion model. **Bone** **46**:418–424, 2010
- 5 24. Neuhuber B, Timothy Himes B, Shumsky JS, Gallo G, Fischer I: Axon growth  
6 and recovery of function supported by human bone marrow stromal cells in the  
7 injured spinal cord exhibit donor variations. **Brain Res** **1035**:73–85, 2005
- 8 25. Ren J, Jin P, Sabatino M, Balakumaran A, Feng J, Kuznetsov SA, et al: Global  
9 transcriptome analysis of human bone marrow stromal cells (BMSC) reveals  
10 proliferative, mobile and interactive cells that produce abundant extracellular  
11 matrix proteins, some of which may affect BMSC potency. **Cytotherapy**  
12 **13**:661–674, 2011
- 13 26. Spilker MH, Yannas IV, Kostyk SK, Norregaard TV, Hsu HP, Spector M: The  
14 effects of tubulation on healing and scar formation after transection of the adult  
15 rat spinal cord. **Restor Neurol Neurosci** **18**:23–38, 2001
- 16 27. Toritsuka M, Kimoto S, Muraki K, Landek-Salgado MA, Yoshida A, Yamamoto  
17 N, et al: Deficits in microRNA-mediated Cxcr4/Cxcl12 signaling in  
18 neurodevelopmental deficits in a 22q11 deletion syndrome mouse model. **Proc**

- 1           **Natl Acad Sci U S A 110:17552–17557, 2013**
- 2   28.    Urdzikova L, Jendelova P, Glogarova K, Burian M, Hajek M, Sykova E:  
3           Transplantation of bone marrow stem cells as well as mobilization by  
4           granulocyte-colony stimulating factor promotes recovery after spinal cord injury  
5           in rats. **J Neurotrauma 23:1379–1391, 2006**
- 6   29.    Williams RR, Henao M, Pearse DD, Bunge MB: Permissive Schwann cell  
7           graft/spinal cord interfaces for axon regeneration. **Cell Transplant 24:115–131,**  
8           2015
- 9   30.    Wright KT, El Masri W, Osman A, Chowdhury J, Johnson WE: Concise review:  
10          Bone marrow for the treatment of spinal cord injury: mechanisms and clinical  
11          applications. **Stem Cells 29:169–178, 2011**
- 12   31.    Yamaya S, Ozawa H, Kanno H, Kishimoto KN, Sekiguchi A, Tateda S, et al:  
13          Low-energy extracorporeal shock wave therapy promotes vascular endothelial  
14          growth factor expression and improves locomotor recovery after spinal cord  
15          injury. **J Neurosurg 121:1514–1525, 2014**
- 16   32.    Yang J, Yamato M, Nishida K, Ohki T, Kanzaki M, Sekine H, et al: Cell delivery  
17          in regenerative medicine: the cell sheet engineering approach. **J Control**  
18          **Release 116:193–203, 2006**

- 1 33. Zeng X, Zeng YS, Ma YH, Lu LY, Du BL, Zhang W, et al: Bone marrow  
2 mesenchymal stem cells in a three-dimensional gelatin sponge scaffold attenuate  
3 inflammation, promote angiogenesis, and reduce cavity formation in  
4 experimental spinal cord injury. **Cell Transplant** **20**:1881–1899, 2011
- 5 34. Zhang LX, Yin YM, Zhang ZQ, Deng LX: Grafted bone marrow stromal cells: a  
6 contributor to glial repair after spinal cord injury. **Neuroscientist** **21**:277–289,  
7 2015.
- 8

1 **Figure legends**

2

3 **Figure 1.** BMSC sheets are permissive for axonal growth and astrocyte extension. (A  
4 and B) The appearance of a BMSC sheet. The sheet could be scraped and picked up  
5 with forceps. (C–E) Double labeling of ECM proteins, collagen I (C), collagen IV (D),  
6 laminin (E), and actin with phalloidin in BMSC sheets. The sheets were  
7 immunoreactive for collagen I and laminin, but not for collagen IV. (F) Neurospheres  
8 were cultured on a BMSC sheet for 3.5 days. Immunocytochemistry using Tuj1 and  
9 GFAP revealed extending Tuj1-positive neurites and processes of GFAP-positive  
10 astrocytes. All scale bars are 100  $\mu$ m.

11

12 **Figure 2.** A T8 laminectomy was performed and the spinal cord was transected at the  
13 same level with a 2-mm defect (A, arrow). A BMSC sheet (B) or GS (C) was  
14 transplanted into the defect in contact with both spinal stumps (arrowheads).

15

16 **Figure 3.** The transplantation of BMSC sheets promoted axonal regeneration across the  
17 BMSC sheet-transplanted site. All sections were sliced in the coronal plane. The  
18 majority of Tuj1-positive axons at the sheet-transplanted site overlapped with

1 GAP43-positive axons at 2 weeks after transplantation (A, arrow). Many more  
2 Tuj1-positive axons beyond the GFAP-positive glial scar were observed at the  
3 sheet-transplanted site compared with the GS-transplanted site at 2 and 8 weeks after  
4 transplantation (B, C, the upper and lower figures are the rostral and caudal sides,  
5 respectively). At 8 weeks after transplantation, elongated Tuj1-positive axons across the  
6 transplanted site were observed only in the sheet-transplanted animals (arrow), but not  
7 in the GS-transplanted animals (arrowhead) (C). The number of axons with a length of  
8 at least 50  $\mu\text{m}$  was counted within the two rectangles 400  $\mu\text{m}$  away from the rostral or  
9 caudal stump of the injury site (D, counting areas are within the green boxes). The  
10 numbers of axons obtained from nine sections at 80- $\mu\text{m}$  intervals were summed (E,  
11 sheet;  $n = 4$ , GS;  $n = 4$ , \*Welch's test  $p < 0.05$ ). All scale bars are 200  $\mu\text{m}$ .

12

13 **Figure 4.** BMSC sheets inhibited glial scar formation and resulted in an irregular glial  
14 scar shape. GFAP immunoreactivity in the rostral and caudal stumps of the spinal cord  
15 appeared to be weaker in the sheet-transplanted animals compared with the  
16 GS-transplanted animals at 2 and 8 weeks after transplantation (A, B, the upper and  
17 lower figures are the rostral and caudal sides, respectively). At 8 weeks after  
18 transplantation, high-magnification images of GFAP immunoreactivity showed irregular

1 shapes lengthwise in the rostro-caudal direction in the sheet-transplanted animals, and  
2 sharp shapes at the rostral and caudal stumps in the GS-transplanted animals (C).  
3 GFAP-positive areas within the two rectangles including the rostral or caudal edge of  
4 the injury site are shown (D, the calculated area is in the black-lined boxes).  
5 GFAP-positive areas obtained from nine sections at 80- $\mu$ m intervals were summed (E,  
6 all groups,  $n = 4$ , \*\*t-test  $p < 0.01$  vs. GS). All scale bars are 200  $\mu$ m.

7

8 **Figure 5.** The hind limb locomotor assessment. The graph shows BBB scores in  
9 sheet-transplanted and GS-transplanted animals at 1, 2, 4, and 8 weeks after  
10 transplantation. Data are presented as the mean  $\pm$  SEM. Sheet group,  $n = 6$ ; GS group,  $n$   
11  $= 6$ . \* $p < 0.05$  vs. GS.

12

13

14

- 15 1. Abrams MB, Dominguez C, Pernold K, Reger R, Wiesenfeld-Hallin Z, Olson L, et al:  
16 Multipotent mesenchymal stromal cells attenuate chronic inflammation and  
17 injury-induced sensitivity to mechanical stimuli in experimental spinal cord injury.  
18 *Restor Neurol Neurosci* 27:307-321, 2009
- 19 2. Akahane M, Nakamura A, Ohgushi H, Shigematsu H, Dohi Y, Takakura Y:  
20 Osteogenic matrix sheet-cell transplantation using osteoblastic cell sheet resulted in  
21 bone formation without scaffold at an ectopic site. *J Tissue Eng Regen Med*  
22 2:196-201, 2008
- 23 3. Akahane M, Shigematsu H, Tadokoro M, Ueha T, Matsumoto T, Tohma Y, et al:

- 1 Scaffold-free cell sheet injection results in bone formation. *J Tissue Eng Regen Med*  
2 4:404-411, 2010
- 3 4. Ankeny DP, McTigue DM, Jakeman LB: Bone marrow transplants provide tissue  
4 protection and directional guidance for axons after contusive spinal cord injury in  
5 rats. *Exp Neurol* 190:17-31, 2004
- 6 5. Basso DM, Beattie MS, Bresnahan JC, Anderson DK, Faden AI, Gruner JA, et al:  
7 MASCIS evaluation of open field locomotor scores: effects of experience and  
8 teamwork on reliability. Multicenter Animal Spinal Cord Injury Study. *J*  
9 *Neurotrauma* 13:343-359, 1996
- 10 6. Castro RF, Jackson KA, Goodell MA, Robertson CS, Liu H, Shine HD: Failure of  
11 bone marrow cells to transdifferentiate into neural cells in vivo. *Science* 297:1299,  
12 2002
- 13 7. Chen MH, Chen PR, Hsieh ST, Huang JS, Lin FH: An in vivo study of tricalcium  
14 phosphate and glutaraldehyde crosslinking gelatin conduits in peripheral nerve  
15 repair. *J Biomed Mater Res B Appl Biomater* 77:89-97, 2006
- 16 8. Chopp M, Zhang XH, Li Y, Wang L, Chen J, Lu D, et al: Spinal cord injury in rat:  
17 treatment with bone marrow stromal cell transplantation. *Neuroreport*  
18 11:3001-3005, 2000
- 19 9. Coyne TM, Marcus AJ, Woodbury D, Black IB: Marrow stromal cells transplanted to  
20 the adult brain are rejected by an inflammatory response and transfer donor labels  
21 to host neurons and glia. *Stem Cells* 24:2483-2492, 2006
- 22 10. Dasari VR, Veeravalli KK, Dinh DH: Mesenchymal stem cells in the treatment of  
23 spinal cord injuries: A review. *World J Stem Cells* 6:120-133, 2014
- 24 11. Davis JB, Stroobant P: Platelet-derived growth factors and fibroblast growth factors  
25 are mitogens for rat Schwann cells. *J Cell Biol* 110:1353-1360, 1990
- 26 12. Hokari M, Kuroda S, Shichinohe H, Yano S, Hida K, Iwasaki Y: Bone marrow  
27 stromal cells protect and repair damaged neurons through multiple mechanisms. *J*  
28 *Neurosci Res* 86:1024-1035, 2008
- 29 13. Horii-Hayashi N, Sasagawa T, Hashimoto T, Kaneko T, Takeuchi K, Nishi M: A  
30 newly identified mouse hypothalamic area having bidirectional neural connections  
31 with the lateral septum: the perifornical area of the anterior hypothalamus rich in  
32 chondroitin sulfate proteoglycans. *Eur J Neurosci* 42:2322-2334, 2015
- 33 14. Horii-Hayashi N, Sasagawa T, Matsunaga W, Nishi M: Development and Structural  
34 Variety of the Chondroitin Sulfate Proteoglycans-Contained Extracellular Matrix in  
35 the Mouse Brain. *Neural Plast* 2015:256389, 2015
- 36 15. Huang YC, Huang YY: Biomaterials and strategies for nerve regeneration. *Artif*  
37 *Organs* 30:514-522, 2006

- 1 16. Ide C, Nakai Y, Nakano N, Seo TB, Yamada Y, Endo K, et al: Bone marrow stromal  
2 cell transplantation for treatment of sub-acute spinal cord injury in the rat. *Brain*  
3 *Res* 1332:32-47, 2010
- 4 17. Ju YE, Janmey PA, McCormick ME, Sawyer ES, Flanagan LA: Enhanced neurite  
5 growth from mammalian neurons in three-dimensional salmon fibrin gels.  
6 *Biomaterials* 28:2097-2108, 2007
- 7 18. Kamada T, Koda M, Dezawa M, Anahara R, Toyama Y, Yoshinaga K, et al:  
8 Transplantation of human bone marrow stromal cell-derived Schwann cells reduces  
9 cystic cavity and promotes functional recovery after contusion injury of adult rat  
10 spinal cord. *Neuropathology* 31:48-58, 2011
- 11 19. Kang KN, Lee JY, Kim da Y, Lee BN, Ahn HH, Lee B, et al: Regeneration of  
12 completely transected spinal cord using scaffold of  
13 poly(D,L-lactide-co-glycolide)/small intestinal submucosa seeded with rat bone  
14 marrow stem cells. *Tissue Eng Part A* 17:2143-2152, 2011
- 15 20. Kira T, Omokawa S, Akahane M, Shimizu T, Nakano K, Nakanishi Y, et al:  
16 Effectiveness of Bone Marrow Stromal Cell Sheets in Maintaining Random-Pattern  
17 Skin Flaps in an Experimental Animal Model. *Plast Reconstr Surg* 136:624e-632e,  
18 2015
- 19 21. Lalu MM, McIntyre L, Pugliese C, Fergusson D, Winston BW, Marshall JC, et al:  
20 Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic  
21 review and meta-analysis of clinical trials. *PLoS One* 7:e47559, 2012
- 22 22. Mannari T, Sawa H, Furube E, Fukushima S, Nishikawa K, Nakashimna T, et al:  
23 Antidepressant-induced vascular dynamics in the hippocampus of adult mouse brain.  
24 *Cell Tissue Res* 358:43-55, 2014
- 25 23. Nakamura A, Akahane M, Shigematsu H, Tadokoro M, Morita Y, Ohgushi H, et al:  
26 Cell sheet transplantation of cultured mesenchymal stem cells enhances bone  
27 formation in a rat nonunion model. *Bone* 46:418-424, 2010
- 28 24. Neuhuber B, Timothy Himes B, Shumsky JS, Gallo G, Fischer I: Axon growth and  
29 recovery of function supported by human bone marrow stromal cells in the injured  
30 spinal cord exhibit donor variations. *Brain Res* 1035:73-85, 2005
- 31 25. Ren J, Jin P, Sabatino M, Balakumaran A, Feng J, Kuznetsov SA, et al: Global  
32 transcriptome analysis of human bone marrow stromal cells (BMSC) reveals  
33 proliferative, mobile and interactive cells that produce abundant extracellular  
34 matrix proteins, some of which may affect BMSC potency. *Cytherapy* 13:661-674,  
35 2011
- 36 26. Spilker MH, Yannas IV, Kostyk SK, Norregaard TV, Hsu HP, Spector M: The effects  
37 of tubulation on healing and scar formation after transection of the adult rat spinal

1 cord. *Restor Neurol Neurosci* 18:23-38, 2001

2 27. Toritsuka M, Kimoto S, Muraki K, Landek-Salgado MA, Yoshida A, Yamamoto N, et  
3 al: Deficits in microRNA-mediated Cxcr4/Cxcl12 signaling in neurodevelopmental  
4 deficits in a 22q11 deletion syndrome mouse model. *Proc Natl Acad Sci U S A*  
5 110:17552-17557, 2013

6 28. Urdzikova L, Jendelova P, Glogarova K, Burian M, Hajek M, Sykova E:  
7 Transplantation of bone marrow stem cells as well as mobilization by  
8 granulocyte-colony stimulating factor promotes recovery after spinal cord injury in  
9 rats. *J Neurotrauma* 23:1379-1391, 2006

10 29. Williams RR, Henao M, Pearse DD, Bunge MB: Permissive Schwann cell  
11 graft/spinal cord interfaces for axon regeneration. *Cell Transplant* 24:115-131, 2015

12 30. Wright KT, El Masri W, Osman A, Chowdhury J, Johnson WE: Concise review: Bone  
13 marrow for the treatment of spinal cord injury: mechanisms and clinical applications.  
14 *Stem Cells* 29:169-178, 2011

15 31. Yamaya S, Ozawa H, Kanno H, Kishimoto KN, Sekiguchi A, Tateda S, et al:  
16 Low-energy extracorporeal shock wave therapy promotes vascular endothelial  
17 growth factor expression and improves locomotor recovery after spinal cord injury. *J*  
18 *Neurosurg* 121:1514-1525, 2014

19 32. Yang J, Yamato M, Nishida K, Ohki T, Kanzaki M, Sekine H, et al: Cell delivery in  
20 regenerative medicine: the cell sheet engineering approach. *J Control Release*  
21 116:193-203, 2006


22 33. Zeng X, Zeng YS, Ma YH, Lu LY, Du BL, Zhang W, et al: Bone marrow mesenchymal  
23 stem cells in a three-dimensional gelatin sponge scaffold attenuate inflammation,  
24 promote angiogenesis, and reduce cavity formation in experimental spinal cord  
25 injury. *Cell Transplant* 20:1881-1899, 2011

26 34. Zhang LX, Yin YM, Zhang ZQ, Deng LX: Grafted bone marrow stromal cells: a  
27 contributor to glial repair after spinal cord injury. *Neuroscientist* 21:277-289, 2015

28

29

Figure 1



# Figure 2





Figure 3







Figure 4




Figure 5

